X-FAB Silicon Foundries (XFAB) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
26 Jun, 2026Executive summary
Q3 2025 revenue reached $229 million, up 12% year-over-year and 6% quarter-on-quarter, exceeding guidance; core markets (automotive, industrial, medical) contributed 94% of total revenue.
EBITDA for Q3 was $53.9 million (23.6% margin), up 7% year-over-year and 4% sequentially; EBIT was $23.8 million, down 5% year-over-year but up 10% sequentially.
Net profit for Q3 2025 was $16.6 million, a 36% decrease year-over-year; EPS was $0.13.
Bookings for Q3 2025 were $163 million with a book-to-bill ratio of 0.71; backlog stood at $347 million.
CEO transition announced: Damien Macq to succeed Rudi De Winter in February 2026.
Financial highlights
Gross profit in Q3 2025 was $48.3 million (21.1% margin), down from 24.8% year-over-year.
Cash and cash equivalents at quarter-end were $174.2 million, up $16.5 million from Q2; net debt decreased by $21.1 million.
Capital expenditures for Q3 were $23.5 million; YTD capex reached $179 million; full-year capex expected below $250 million.
Net financial result was -$5.6 million, mainly due to interest expenses.
Headcount averaged 4,278 in Q3 2025, down 2% year-over-year.
Outlook and guidance
Q4 2025 revenue expected between $215 million and $225 million; EBITDA margin guidance 22.5%-25.5%.
Full-year 2025 revenue expected in the range of $863 million-$873 million.
Visibility remains limited due to macroeconomic and geopolitical uncertainties and cautious customer ordering.
Latest events from X-FAB Silicon Foundries
- Q3 revenue up sequentially, automotive strong, industrial/medical weak, guidance lowered.XFAB
Q3 202426 Jun 2026 - Q4 2024 revenue and profit fell amid auto destocking; CapEx to drop and recovery expected in 2025.XFAB
Q4 202426 Jun 2026 - Q1 2026 revenue was $195.6M, with strong growth in industrial, medical, and microsystems.XFAB
Q1 202610 May 2026 - Q4 revenue up 18% YoY to $222.3M; industrial and medical growth offset automotive softness.XFAB
Q4 20259 Feb 2026 - Q2 revenue fell 9% year-on-year to $205.1M; SiC weakness led to lower guidance, but Q4 rebound expected.XFAB
Q2 20242 Feb 2026 - Double-digit growth, major expansions, and $1.5B revenue and 35% margin targeted by 2030.XFAB
Investor Day 202411 Jan 2026 - Three-pillar strategy and $1.1B expansion drive growth in specialty semiconductors.XFAB
CMD 202531 Dec 2025 - Q1 revenue up 8% sequentially, EBITDA margin 24%, guidance and expansion plans reaffirmed.XFAB
Q1 202523 Dec 2025 - Q2 revenue up to 8% year-over-year, guidance raised, and capacity expansion completed.XFAB
Q2 202516 Nov 2025